CO6290706A2 - Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico - Google Patents

Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico

Info

Publication number
CO6290706A2
CO6290706A2 CO10112124A CO10112124A CO6290706A2 CO 6290706 A2 CO6290706 A2 CO 6290706A2 CO 10112124 A CO10112124 A CO 10112124A CO 10112124 A CO10112124 A CO 10112124A CO 6290706 A2 CO6290706 A2 CO 6290706A2
Authority
CO
Colombia
Prior art keywords
nicotinic agonist
combination
pharmaceutical combination
alfa
antipsychotic agent
Prior art date
Application number
CO10112124A
Other languages
English (en)
Spanish (es)
Inventor
Merouane Bencherif
Gregory J Gatto
Kristen Jordan
Terry Hauser
Sharon R Letchworth
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of CO6290706A2 publication Critical patent/CO6290706A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CO10112124A 2008-02-13 2010-09-10 Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico CO6290706A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
CO6290706A2 true CO6290706A2 (es) 2011-06-20

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10112124A CO6290706A2 (es) 2008-02-13 2010-09-10 Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico

Country Status (25)

Country Link
US (1) US20110059947A1 (https=)
EP (2) EP2633868A1 (https=)
JP (1) JP2011511845A (https=)
KR (1) KR20100113163A (https=)
CN (2) CN103143023A (https=)
AU (1) AU2009214625A1 (https=)
BR (1) BRPI0907570A2 (https=)
CA (1) CA2715268A1 (https=)
CO (1) CO6290706A2 (https=)
CY (1) CY1114492T1 (https=)
DK (1) DK2254598T3 (https=)
EC (1) ECSP10010471A (https=)
ES (1) ES2430622T3 (https=)
HR (1) HRP20130749T1 (https=)
IL (1) IL207389A0 (https=)
MX (1) MX2010008875A (https=)
NZ (1) NZ587312A (https=)
PL (1) PL2254598T3 (https=)
PT (1) PT2254598E (https=)
RS (1) RS52941B (https=)
RU (1) RU2481123C2 (https=)
SG (1) SG188144A1 (https=)
SI (1) SI2254598T1 (https=)
WO (1) WO2009102962A2 (https=)
ZA (1) ZA201005999B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
CA2824900A1 (en) * 2011-01-18 2012-07-26 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
WO2012151136A1 (en) * 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
MX2015004285A (es) * 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Derivado de imidazol.
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
CA2396351C (en) * 1999-12-10 2009-11-10 Wyeth New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
KR100751981B1 (ko) * 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
AU2001284645A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282875A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016355A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
CA2476624A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
BR0317019A (pt) * 2002-12-06 2005-10-25 Pharmacia & Upjohn Co Llc Sais cristalinos fumarato de 1-azabiciclo[2.2.2]oct-substituìdo-furo[2,3-c]piridinil- carboxamida e suas composições e preparações
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
WO2009102962A2 (en) 2009-08-20
EP2254598A2 (en) 2010-12-01
CN103143023A (zh) 2013-06-12
PT2254598E (pt) 2013-10-16
RU2010137787A (ru) 2012-03-20
ZA201005999B (en) 2011-05-25
RU2481123C2 (ru) 2013-05-10
HK1147954A1 (en) 2011-08-26
CN101977628A (zh) 2011-02-16
KR20100113163A (ko) 2010-10-20
PL2254598T3 (pl) 2013-12-31
US20110059947A1 (en) 2011-03-10
BRPI0907570A2 (pt) 2019-09-24
EP2633868A1 (en) 2013-09-04
MX2010008875A (es) 2010-08-31
IL207389A0 (en) 2010-12-30
DK2254598T3 (da) 2013-07-29
RS52941B (sr) 2014-02-28
ECSP10010471A (es) 2010-10-30
WO2009102962A3 (en) 2009-10-08
HRP20130749T1 (en) 2013-10-11
NZ587312A (en) 2011-12-22
CY1114492T1 (el) 2016-10-05
SI2254598T1 (sl) 2013-10-30
JP2011511845A (ja) 2011-04-14
SG188144A1 (en) 2013-03-28
EP2254598B1 (en) 2013-07-10
CA2715268A1 (en) 2009-08-20
AU2009214625A1 (en) 2009-08-20
ES2430622T3 (es) 2013-11-21

Similar Documents

Publication Publication Date Title
CO6290706A2 (es) Combinacion sinergica de un agonista nicotinico alfa 7 y un agente antipsicotico
CO2019005287A2 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
BR112015020584A2 (pt) métodos para o tratamento de artrite psoriática usando apremilast
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
MY155275A (en) 4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-n-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof
EA200870376A1 (ru) Бензотиазолы, обладающие активностью по отношению к h3-рецептору гистамина
CR11369A (es) Anticuerpo anti-glipican-3 que tiene cineticas mejoradas en el plasma
CL2008003902A1 (es) Formulación farmacéutica que comprende tetrahidrocannabidivirina (thcv) y/o cannabidiol (cbd) junto a aripiprazol o un metabolito del mismo y su uso en la prevención o el tratamiento de la psicosis o de un trastorno psicótico.
CL2010001160A1 (es) Compuestos derivados de 3,8-diazabiciclo[4.2.0]octano y 3,6-diazabiciclo[3.2.0]heptano; composicion farmaceutica; moduladores del reeptor de la orexina, utiles en el tratamiento del insomnio.
CL2008001951A1 (es) Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras.
CR20160544A (es) Compuesto heterocíclico que contiene nitrógeno
NZ604592A (en) Combinations comprising atypical antipsychotics and taar1 agonists
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ATE533947T1 (de) Einsetzausrüstung und installationsverfahren
CL2020001851A1 (es) Moduladores de la expresión dnm2
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
UY28225A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
AR057643A1 (es) Lacosamida para terapia adjunta
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP10010698A (es) Derivados de dibenzotiazepina y sus usos

Legal Events

Date Code Title Description
FC Application refused